Purpose In March 2007, a legislative amendment was issued in Sweden compelling nurses to report all suspected adverse drug reactions (ADRs) to the national pharmacovigilance system. The aims of this study were to describe the status of ADR reporting, before and after the implementation of the legislative changes, and to describe the general characteristics of suspected ADRs reported by nurses. Methods The Swedish pharmacovigilance system during the study period constituted six regional centres responsible for the handling of all spontaneous ADR reports within their region. In this study, we identified all individual ADR reports from 2005 and 2010, analysed in depth the ADR reports from two regional centres and collated information about the reporter and the nature of the reported ADR. Conclusions The overall ADR reporting by nurses did not appear to increase after the change in reporting legislation. The proportion of serious and/or unlabelled ADRs reported by nurses did however appear to increase during the same period. Taken together, our data suggests that further proactive measures should be considered in order to involve nurses in the reporting of suspected ADRs.
Introduction
Adverse drug reactions (ADRs) are one of the most common causes of morbidity and mortality and constitute a major problem both in medical and economical terms [1] [2] [3] [4] [5] . Post marketing, spontaneous reporting of suspected ADRs is an essential part of an effective pharmacovigilance system. The goal of ADR reporting systems is to increase patient safety by collecting information about suspected ADRs in order to detect previously unknown ADRs or obtain new information on known ADRs. Underreporting is however a major challenge in the identification and characterisation of suspected ADRs. A review article from 2006 showed that the underreporting is a serious problem with rates of reporting varying between 0 and 94 %, with an overall average report rate of 6 % [6] . Several reasons for underreporting of ADRs have been suggested including a lack of knowledge on how to report ADRs, misconception that absolute confidence in the diagnosis of an ADR is necessary and lack of time among health-care professionals [7] .
Nurses in particular have close contact with patients and are generally responsible for the administration of drug therapy in hospitalised patients. As a result of their role in patient care, nurses have the potential to play a valuable role in the enhancement of pharmacovigilance systems. Previous studies on ADR reporting have shown that the quantity, quality and information gained from ADR reports are markedly increased if nurses are included in the reporting system [8] [9] [10] [11] [12] [13] . In Sweden, reporting of suspected ADRs has been mandatory since 1975 for physicians, dentists and nurses with prescription privileges [14] . Among nurses with prescription privileges in Sweden, the proportion of nurses reporting ADRs has increased from 2-3 % in the 1990s to 12 % in 2004 [11] . In order to increase the overall reporting of ADRs, a legislative amendment was issued in Sweden in March 2007, where all nurses were included as reporters of suspected ADRs [15] . The effects of the new legislation on suspected ADR reporting has, however, not been evaluated. The aims of this study were therefore to describe ADR reporting from health-care professionals in Sweden, before and after the change in the legislation, and to describe the characteristics of the reported ADRs by nurses.
Methods
Since 1965, Sweden has a spontaneous reporting system for suspected ADRs. Until 2012, the pharmacovigilance system in Sweden consisted of six regional centres, which handled the spontaneous ADR reports within their region. Within the pharmacovigilance system, all suspected serious, uncommon or otherwise unexpected ADRs were supposed to be reported. Moreover, reporting of all ADRs was encouraged during the first 2 years after drug approval. Information from each individual report was stored in the national database, the Swedish Drug Information System (SWEDIS). Data stored in the database consisted of information about the patient, drugs used, suspected ADRs, outcome, causality assessment, the reporter, origin of the report and administrative data. Until 2012, the WHO definition of an ADR, Ba response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, therapy of disease, or for the modification of physiological function^, was used within the Swedish spontaneous reporting system [16] .
In SWEDIS, drugs can be listed as being suspected of having caused or contributed to the reaction, as interacting with another prescribed drug, or as concomitant medication not related to the ADR. Drugs were coded according to the WHO Collaborating Centre for Drug Statistics Methodology International Anatomical Therapeutic Chemical (ATC) classification [17] . The ADRs were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) terminology [18] . Each report may include more than one ADR and/or drug. Each ADR was classified with respect to its causality using the WHO definitions [16] and seriousness [19] . The reported ADRs were classified as unlabelled if the reported reactions were not included in the ADR section of the Summary of Product Characteristics (SPC) at the time when the ADR was reported.
All individual ADR reports from 1st of January to 31st of December of 2005 and 2010 were identified in SWEDIS. The ADR reports from the Southeast regional pharmacovigilance centre and the Northern regional pharmacovigilance centre in Sweden were collected and scrutinised. The population living in the two regions comprised 21 % (1,860,582 individuals) in 2005 and 20 % (1,877,255 individuals) in 2010 of the Swedish population and included a population with similar age and gender distribution as Sweden in total [20] . Information on the reporter (sex and profession) and the reported ADR (MedDRA classification, administered drugs, seriousness, labelling in the SPC and causality assessment) was extracted from the ADR reports. Reporters were categorised as nurse (working in primary care, in hospital or in school health care), physician (working in primary care or in hospital) and other (dentist). The other category also included reports submitted from other health-care professionals not obligated to report ADRs, including reports from dental hygienists, pharmacists and laboratory technicians. Information about the physicians' level of education and medical specialists training were identified in a register of all physicians in Sweden.
The data were analysed descriptively. For each reporter category (physician, nurse and other), the proportions of reported ADRs, serious and/or unlabelled ADRs, were calculated. Furthermore, serious and/or unlabelled ADRs reported by nurses were described in more detail.
Results
In total, 4065 reports were submitted to the Swedish (Table 3 ). In 2010, the spectrum of suspected drugs among serious and/or unlabelled ADRs also included reports from e.g. anti-bacterials, nervous system drugs, contrast media and drugs for treatment of bone disease and obstructive airways.
Discussion
This retrospective study indicates that the proportion of ADRs reported by nurses in the Southeast and Northern pharmacovigilance centres in Sweden did not increase after the legislative amendment that included all nurses as reporters of suspected ADRs. There did however appear to be an increase in number of ADR reports from nurses working outside the school health care and in the proportion of serious and/or unlabelled ADRs from nurses in general. This suggests a shift after the legislative amendment towards nurses reporting more ADRs that add new information within the pharmacovigilance system.
In this study, the number of ADR reports from nurses seemed to decrease in 2010 compared to 2005. The main decrease was observed among nurses working in school health care, where a 50 % reduction occurred. These nurses administer vaccinations within the Swedish childhood vaccination programme and a large part of their reports concern 
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214 (24) 137 (13) 168 (30) 88 (13) 46 (14) 49 (12) All physicians b 601 (67) 803 (75) 342 (61) 498 (73) 259 (77) 305 (77) Physicians working as general practitioner 207 (23) 161 (15) 99 (18) 84 (12) 108 (32) 77 (20) Physicians working in hospital 394 (44) 640 (60) 243 (43) 412 (61) 151 (45) 228 (58) Others c 22 (2) 11 (1) 10 (2) 6 (1) 12 (4) 5 (1) [23] . In Portugal, nurses have been included as reporters since the start of the Portuguese pharmacovigilance system in 1992 and have therefore a longer tradition of reporting ADRs. In a Swedish survey from 2010 [9] , a random sample of 753 nurses who were members in one of two trade unions, the Swedish Association of Health Professionals (engaged 75,300 Swedish nurses at the time), were included. Of the 453 nurses that responded to the survey, 58 % reported that they were aware of their role as reporters of suspected ADRs but only 14 % stated that they had reported an ADR. Nurses' involvement in pharmacovigilance activities in Sweden could hence be further encouraged.
Although the number of ADR reports from nurses in this study appeared to decrease during the study period, there seemed to be an increased reporting of serious and/or unlabelled reactions. Similar results have been shown in an Italian study [8] , where the reporting rate of serious reactions from Italian nurses increased from 13 % in 2004 to 26 % in 2010. A closer observation of all serious and/or unlabelled ADRs reported by nurses in this study showed a broadened spectrum of suspected drugs in 2010 compared to 2005, even if vaccines still accounted for the majority of suspected drug reactions. In addition to vaccines, nurses' reports on serious ADRs also included anti-bacterials, anti-epileptics and drugs for treatment of bone disease and obstructive airways.
This study shows that the reporting of ADRs by physicians was not negatively affected by the inclusion of nurses as ADR reports, since the number of ADR reports from physicians increased in 2010 compared to 2005. In a Swedish pilot study of nursing reporting in Sweden [13] , 89 % of the physicians stated that their own willingness to report was not affected by nurses reporting. Moreover, in a Swedish survey [24] , the majority of hospital physicians in Sweden reported that they were positive or neutral to nurses reporting. Further studies are however needed to assess the effect on physicians' reporting.
The main limitation of this study is that we were not able to take other factors into consideration that might have affected the reporting rate during the study period, such as media attention on specific ADRs. 17 (7) 286 (48) 393 (49) 8 ( (23) 281 (26) 11 (4) 45 (17) 194 (32) 232 (29) 5 (23) 4 (36)
Causality assessed as at least possible b 842 (94) 1010 (94) 272 (99) 254 (98) 548 (91) 745 (93) 22 (100) 11 ( 
Conclusions
The overall ADR reporting from nurses was in the same order of magnitude after the inclusion of all nurses as reporters.
There was an increase in reports from nurses working in primary care and hospitals, and there also appeared to be an increase of serious and/or unlabelled ADR reports from nurses in general after the legislative amendment. Most of the nurses' ADR reports that were classified as serious and/or unlabelled reactions were related to vaccine administration. Taken together, our data suggests that further pro-active measures should be considered in order to involve nurses in the reporting of suspected ADRs.
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